First Trust Nasdaq Pharmaceuticals ETF
FTXH
19 hedge funds and large institutions have $12M invested in First Trust Nasdaq Pharmaceuticals ETF in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
27% more funds holding
Funds holding: 15 → 19 (+4)
2.11% less ownership
Funds ownership: 64.13% → 62.02% (-2.1%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
20% less capital invested
Capital invested by funds: $15M → $12M (-$3.04M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LJAC
L.J. Altfest & Co
New York
|
+$4.35M |
| 2 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$1.42M |
| 3 |
Goldman Sachs
New York
|
+$525K |
| 4 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
+$243K |
| 5 |
LPL Financial
San Diego,
California
|
+$182K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
-$9.07M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$421K |
| 3 |
FHA
Flagship Harbor Advisors
Boston,
Massachusetts
|
-$180K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$75K |
| 5 |
LGA
Lebenthal Global Advisors
Hauppauge,
New York
|
-$16K |
FTXH Hedge Fund Activity: Q1 2021 in Review
19 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2021, worth a combined $12M — down 20% from $15M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new FTXH positions and 1 closed out — a net gain of 4 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was L.J. Altfest & Co, opening a new position worth an estimated $4.35M. The largest seller was J. Arnold Wealth Management, cutting an estimated $9.07M.
- 19 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2021, up from 15 in Q4 2020.
- Funds reported $12M of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2021, down 20% quarter-over-quarter.
- 5 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2021 and 1 closed out, a net change of +4 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2021 was L.J. Altfest & Co, an estimated $4.35M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2021 was J. Arnold Wealth Management, an estimated $9.07M sold.
Based on aggregated 13F filings for Q1 2021.